New combination therapy for non-Hodgkin lymphoma
Official title: Translation of a novel combination therapy approach for non-Hodgkin lymphoma
Funded at Mayo Clinic Rochester · NIH-11211672 · Data updated 2026-11-12
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $121,055 |
| NIH project number | 3U01CA272257-04S1 |
| Project ID | NIH-11211672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with relapsed or refractory diffuse large B-cell lymphoma and similarly affected companion dogs that meet the trial’s health and eligibility criteria.
✕Less likely to help
Patients with other lymphoma subtypes, early-stage disease well controlled by standard therapy, or medical conditions that prevent receiving an oncolytic virus or immunotherapy may not benefit from this approach.
What this research studies
This work combines an engineered oncolytic virus (VSV) given intravenously with immune checkpoint drugs to try to make resistant diffuse large B-cell lymphoma more responsive to treatment. Researchers will study how the tumor microenvironment and immune cells change after treatment and monitor safety and side effects. The project uses naturally occurring lymphoma in companion dogs alongside laboratory and translational studies to mirror how the approach may work in people. Findings from the canine patients and lab analyses will guide how this combination might be used in future human treatments.
Why it matters
Potential benefit: If successful, this approach could make immunotherapy work for some people with relapsed or refractory DLBCL and offer a new option when standard treatments fail.
How similar studies have gone: Checkpoint inhibitors have worked well in Hodgkin lymphoma but not reliably in NHL, and oncolytic viruses have shown promise preclinically and in early trials, so this combination is promising but still experimental.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Naik, Shruthi — Mayo Clinic Rochester
- Study coordinator: Naik, Shruthi
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination treatment for diffuse large B‑cell lymphoma
This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.